{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:22:04Z","timestamp":1778070124181,"version":"3.51.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project","award":["2026ZF71"],"award-info":[{"award-number":["2026ZF71"]}]},{"name":"the Medical and Health Science Program of Zhejiang Province","award":["2025HY0747"],"award-info":[{"award-number":["2025HY0747"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:p>\n                    Erythropoiesis-stimulating agents (ESAs) are widely used to treat anemia, but their on-target effects on tumor risk via erythropoietin (EPO)\/erythropoietin receptor (EPOR) signaling remain debated. This study aims to evaluate the potential causal relationship between EPO signaling and the risk of 14 site-specific cancers using a drug-target Mendelian randomization (MR) approach. We proxied EPO signaling using genetic instruments for the EPOR, derived from cis-expression quantitative trait locus data from the eQTLGen Consortium. Summary-level genetic associations for 14 cancer types were sourced from the FinnGen consortium (R12 release). We applied the inverse variance weighted method as the primary analysis, supplemented by MR-Egger, weighted median, weighted mode, and simple mode approaches. Sensitivity analyses, including Cochran\n                    <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                    test and pleiotropy-robust methods, were conducted to assess heterogeneity and validate result reliability. Overall, genetically proxied EPO exposure was significantly associated with an increased risk of prostate cancer (odds ratio: 1.07, 95% confidence interval: 1.02\u20131.12,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20053.30\u2005\u00d7\u200510\n                    <jats:sup>\u20103<\/jats:sup>\n                    ), and this association remained statistically significant after multiple testing correction. A suggestive association was also observed for bladder cancer (odds ratio: 1.12, 95% confidence interval: 1.03\u20131.21,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20056.34\u2005\u00d7\u200510\n                    <jats:sup>\u20103<\/jats:sup>\n                    ), though it did not survive strict correction for multiple comparisons. No significant associations were detected for the other 12 cancer types. Sensitivity analyses revealed no substantial heterogeneity or horizontal pleiotropy, supporting the robustness of the primary findings. This MR study provides novel genetic evidence supporting a potential causal role of EPO\/EPOR signaling in prostate carcinogenesis, with a suggestive signal for bladder cancer. These findings highlight the importance of further investigating the tissue-specific oncogenic roles of EPO and underscore the need for cautious interpretation regarding the long-term safety of ESAs. In particular, the observed association with prostate cancer suggests that patients receiving ESAs for anemia management may warrant urological monitoring, although further validation is required. Future large-scale prospective studies and mechanistic investigations are warranted to validate these results and clarify their clinical relevance.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048078","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:01:13Z","timestamp":1773432073000},"page":"e48078","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Erythropoietin drug targets and cancer risk: A two-sample Mendelian randomization study"],"prefix":"10.1097","volume":"105","author":[{"given":"Hailing","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2519-2654","authenticated-orcid":false,"given":"Heran","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260506","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260506","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000356193","article-title":"Physiology and pharmacology of erythropoietin.","volume":"40","author":"Jelkmann","year":"2013","journal-title":"Transfus Med Hemother"},{"key":"R3-20260506","first-page":"CD003407","article-title":"Erythropoietin or darbepoetin for patients with cancer.","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-20260506","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update.","volume":"37","author":"Bohlius","year":"2019","journal-title":"J Clin Oncol"},{"key":"R5-20260506","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.3390\/cells10082140","article-title":"Erythropoietin (EPO) as a key regulator of erythropoiesis, bone remodeling and endothelial transdifferentiation of multipotent Mesenchymal Stem Cells (MSCs): implications in regenerative medicine.","volume":"10","author":"Tsiftsoglou","year":"2021","journal-title":"Cells"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"eadr3026","DOI":"10.1126\/science.adr3026","article-title":"Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity.","volume":"388","author":"Chiu","year":"2025","journal-title":"Science"},{"key":"R7-20260506","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tem.2012.10.007","article-title":"Erythropoietin in cancer: a dilemma in risk therapy.","volume":"24","author":"Cao","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/ijc.32917","article-title":"End of an era for erythropoiesis-stimulating agents in oncology.","volume":"146","author":"Schoen","year":"2020","journal-title":"Int J Cancer"},{"key":"R9-20260506","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10238-022-00921-1","article-title":"Effect of erythropoiesis-stimulatingagents on breast cancer patients: a meta-analysis.","volume":"23","author":"Wu","year":"2023","journal-title":"Clin Exp Med"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"1420625","DOI":"10.3389\/fcimb.2024.1420625","article-title":"A causal association between esophageal cancer and the oral microbiome: a Mendelian randomization study based on an Asian population.","volume":"14","author":"Hu","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/s41467-024-46927-z","article-title":"Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancers.","volume":"15","author":"Went","year":"2024","journal-title":"Nat Commun"},{"key":"R12-20260506","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1038\/s41467-024-50385-y","article-title":"A robust cis-Mendelian randomization method with application to drug target discovery.","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"R13-20260506","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets.","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"},{"key":"R14-20260506","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4103\/aja.aja_80_19","article-title":"Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer.","volume":"22","author":"Ye","year":"2020","journal-title":"Asian J Androl"},{"key":"R15-20260506","doi-asserted-by":"crossref","first-page":"844794","DOI":"10.3389\/fonc.2022.844794","article-title":"Pan-cancer analysis based on EPOR expression with potential value in prognosis and tumor immunity in 33 tumors.","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"R16-20260506","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41419-020-2276-8","article-title":"Erythropoietin and its derivatives: from tissue protection to immune regulation.","volume":"11","author":"Peng","year":"2020","journal-title":"Cell Death Dis"},{"key":"R17-20260506","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1541-7786.MCR-20-0746","article-title":"Multiorgan signaling mobilizes tumor-associated erythroid cells expressing immune checkpoint molecules.","volume":"19","author":"Sano","year":"2021","journal-title":"Mol Cancer Res"},{"key":"R18-20260506","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1182\/blood-2009-10-248674","article-title":"Absence of functional EpoR expression in human tumor cell lines.","volume":"115","author":"Swift","year":"2010","journal-title":"Blood"},{"key":"R19-20260506","doi-asserted-by":"crossref","first-page":"E1185","DOI":"10.1152\/ajpendo.00272.2018","article-title":"Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.","volume":"315","author":"Gagliano-Juc\u00e1","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R20-20260506","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.62347\/UJAT9290","article-title":"Recurrence risk of erythropoiesis-stimulating agents on early-stage urothelial carcinoma in patients with end stage renal disease.","volume":"14","author":"Liu","year":"2024","journal-title":"Am J Cancer Res"},{"key":"R21-20260506","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3892\/or.2014.3428","article-title":"EPO gene expression induces the proliferation, migration and invasion of bladder cancer cells through the p21WAF1\u2011mediated ERK1\/2\/NF-\u03baB\/MMP-9 pathway.","volume":"32","author":"Park","year":"2014","journal-title":"Oncol Rep"},{"key":"R22-20260506","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1186\/s12885-024-13133-5","article-title":"Prospective study on the association between 36 human blood cell traits and pan-cancer outcomes: a mendelian randomization analysis.","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"key":"R23-20260506","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/pcm.2023.5","article-title":"Mendelian randomization as a tool to inform drug development using human genetics.","volume":"1","author":"Daghlas","year":"2023","journal-title":"Camb Prism Precis Med"},{"key":"R24-20260506","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12916-024-03700-9","article-title":"Common pitfalls in drug target Mendelian randomization and how to avoid them.","volume":"22","author":"Gill","year":"2024","journal-title":"BMC Med"},{"key":"R25-20260506","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization.","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:06:44Z","timestamp":1778069204000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048078","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-10-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}